Last reviewed · How we verify
LEO 90100 aerosol foam vehicle
LEO 90100 is a topical aerosol foam vehicle designed to deliver active pharmaceutical ingredients to the skin with improved penetration and patient convenience.
LEO 90100 is a topical aerosol foam vehicle designed to deliver active pharmaceutical ingredients to the skin with improved penetration and patient convenience. Used for Dermatological conditions requiring topical treatment (specific indication dependent on active ingredient formulation).
At a glance
| Generic name | LEO 90100 aerosol foam vehicle |
|---|---|
| Sponsor | LEO Pharma |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 3 |
Mechanism of action
As a vehicle formulation, LEO 90100 functions as a delivery system rather than having its own direct pharmacological mechanism. The aerosol foam format enhances skin penetration and distribution of active ingredients while providing ease of application. The specific active ingredient(s) contained within this vehicle would determine the ultimate therapeutic mechanism.
Approved indications
- Dermatological conditions requiring topical treatment (specific indication dependent on active ingredient formulation)
Common side effects
Key clinical trials
- LEO 90100 Compared to Vehicle in Subjects With Psoriasis Vulgaris (PHASE3)
- LEO 90100 Aerosol Foam Compared to Calcipotriol Plus Betamethasone Dipropionate Gel in Subjects With Psoriasis Vulgaris (PHASE3)
- LEO 90100 Compared With Calcipotriol Plus Betamethasone Dipropionate Ointment, LEO 90100 Vehicle and Ointment Vehicle in Subjects With Psoriasis Vulgaris (PHASE2)
- A Psoriasis Plaque Test Trial With LP0113 Spray in Patients With Psoriasis Vulgaris (LP0113-1123) (PHASE2)
- A Vasoconstriction Study With LEO 90100 (PHASE1)
- Skin Irritation of LEO 90100 Foam (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Healthy Japanese Subjects (PHASE1)
- LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris (PHASE3)
- Vasoconstriction Trial With LEO 90100 Aerosol Foam (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LEO 90100 aerosol foam vehicle CI brief — competitive landscape report
- LEO 90100 aerosol foam vehicle updates RSS · CI watch RSS
- LEO Pharma portfolio CI